
One quarter of bit.bio’s staff axed as stem cell company drops therapeutics division
Synthetic biology company bit.bio has repositioned its business model to focus on its cell manufacturing strengths, downsizing its therapeutics division with the loss of one quarter of its workforce. The reduction of its headcount leaves around 150 …